Openbookopenbook
Equity
Xilio Development Inc(XLO)
USD --+0.00%
Reward47Moderate
Risk56Medium-High
📊75%Data
Thin -184% profit margin · Revenue growing 743% YoY
XLO
+0.0 · +0.00%
USD · NASDAQ
Xilio Development Inc | Healthcare
Value Trap
Market Cap:38.81M
ℹ️
Reward Rating
47
Moderate
Bottom 25% (model universe)
75% data coverage
ℹ️
Risk Rating
56
Medium-High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on XLO to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $2.00.

What is Xilio Development Inc?

, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies.

XLO · Verdict

Moderate reward · elevated risk

XLO stands out on volatility and valuation, but watch the cash flow signal.

Based on 88% data coverage

XLO · Verdict

What’s working & what to watch

Strengths 2

  • Volatility75/100

    Above average

  • Valuation67/100

    Above average

Watchouts 3

  • Cash flow7/100

    -290% free-cash-flow margin

  • Profitability32/100

    -918% net margin · -908% ROE

  • Growth45/100

    Earnings -7.8% CAGR

Model-based scoring. For information only — not financial advice.

What is Xilio Development Inc?

, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 38.81M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Moderate volatility with meaningful macro and earnings sensitivity.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (47)

The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap38.81M
P/E RatioN/A
Dividend YieldN/A
52 Week High1.18
52 Week Low0.503
Last AnnualDecember
IPO Date10/22/2021
IncorporatedUSA
Shares Outstanding73M
No. of Employees64
IndustryBiotechnology
ExchangeNASDAQ
Beta-0.037
CurrencyUSD
Websitexiliotx.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.